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Abstract A majority (84%) of G protein-coupled receptors
have a proline (P5.50) in the middle of the ¢fth transmembrane
domain. However, one of the unique structural features of can-
nabinoid receptors is the replacement of the conserved P5.50 by
a leucine (L5.50). It has been shown that a conserved tyrosine
(Y5.58), located at the cytoplasmic side of P5.50, is crucial for
the signal transduction of several G protein-coupled receptors.
We proposed that the replacement of P5.50 by L5.50 and the
presence of the conserved Y5.58 in this context are important for
the function of CB2. Mutating L5.50 to a proline abolished li-
gand binding, whereas mutating Y5.58 to an alanine resulted in a
rightward shift of the competition binding curves. Both of these
mutations led to a complete loss of the ability of cannabinoid
agonists to inhibit forskolin-stimulated cAMP accumulation.
1 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Marijuana (cannabis) is one of the oldest and most widely
used drugs in the world. It has prominent e¡ects on the cen-
tral nervous system as well as peripheral systems [1]. In 1964,
v9-THC was recognized as the major psychoactive component
of marijuana [2]. Based on their chemical structures, cannabi-
noid agonists can be classi¢ed into four main classes. They are
classical cannabinoids [3], bicyclic cannabinoids [4], aminoal-
kylindoles [5] and fatty acid amines and esters [6,7].
To date, two types of cannabinoid receptors, CB1 [8] and
CB2 [9], have been cloned. CB2 exhibits 44% amino acid
identity with CB1 [9]. CB1 is located in the central nervous
system as well as peripheral tissues [8,10,11]. CB2 is distrib-
uted primarily in peripheral tissues such as immune cells
[9,11]. Many studies have demonstrated the modulatory ef-
fects of cannabinoids on the functions of immune system. It
has been suggested that speci¢c cannabinoid receptors may
mediate the immunomodulatory e¡ects of cannabinoids
[11,12]. It is known that activation of both CB1 and CB2
cannabinoid receptors inhibits adenylate cyclase through cou-
pling with pertussis toxin sensitive G proteins [13,14].
Cannabinoid receptors belong to the rhodopsin family of G
protein-coupled receptors [15^17]. These receptors contain
seven putative transmembrane domains connected by three
extracellular and three intracellular loops. The rhodopsin fam-
ily of G protein-coupled receptors shares several highly con-
served amino acid motifs in their transmembrane domains.
Cannabinoid receptors have most, but not all of these highly
conserved amino acid motifs.
One of the highly conserved features of G protein-coupled
receptors is the presence of several highly conserved prolines
in their transmembrane domains. The presence of proline in
transmembrane helices plays potential structural and dynamic
roles for transmembrane domain functions [18^20]. However,
among the seven transmembrane domains of G protein-
coupled receptors, proline is conserved only in selected trans-
membrane domains. Thus, it is possible that both proline-
containing and proline-lacking transmembrane domains are
important for the functions of G protein-coupled receptors.
A proline residue (P5.50) is located in the middle of ¢fth
transmembrane domains of majority (84%) of G protein-
coupled receptors [17]. However, in cannabinoid receptors
this proline is replaced by a leucine (Fig. 1). We hypothesized
that this unique structural feature of cannabinoid receptors
might be important for their functions. To test this hypothesis
in CB2, we mutated this unique leucine to a proline, as highly
conserved in most G protein-coupled receptors.
Previously, it has been demonstrated that a conserved tyro-
sine (Y5.58), located at the cytoplasmic side of the conserved
proline (P5.50) in the ¢fth transmembrane domain, plays an
important role in the signal transduction of several G protein-
coupled receptors [21,22]. As mentioned above, one of the
unique structural features of cannabinoid receptors is the ab-
sence of proline (P5.50) in the ¢fth transmembrane domain.
However, the highly conserved tyrosine (Y5.58) does exist in
the cannabinoid receptors (Fig. 1). It is unknown, whether in
the absence of P5.50, this tyrosine still has a critical role in the
signal transduction of CB2, as reported for other G protein-
coupled receptors. To answer this question, we converted this
tyrosine (Y5.58) in CB2 to an alanine.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium, fetal bovine serum, penicillin/
streptomycin, L-glutamine, trypsin and geneticin were obtained from
0014-5793 / 02 / $22.00 H 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 5 3 7 - 8
*Corresponding author. Fax: (1)-502-852 7868.
E-mail address: zhsong@louisville.edu (Z.H. Song).
Abbreviations: v9-THC, v9-tetrahydrocannabinol ; HU-210, (3)-11-
hydroxy-v8-tetrahydro-cannabinol-dimethylheptyl; WIN55212-2, (R)-
(+)-[2,3-dihydro-5-methyl-3-[(4-morpho-linyl)methyl)]pyrrolo-[1,2,3-de]-
1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate
FEBS 26687 23-10-02
FEBS 26687FEBS Letters 531 (2002) 290^294
Biowhittaker (Walkersville, MD, USA). Enzymes and reagents used
for recombinant DNA experiments were purchased from Gibco-BRL
(Gaithersburg, MD, USA), or Promega (Madison, WI, USA). Adeno-
virus-transformed 293 cells were obtained from American Type Cul-
ture Collection (Rockville, MD, USA). Glass tubes used for diluting
cannabinoid drugs and for ligand binding assays were silanized
through exposure to dichlorodimethylsilane (Sigma Chemical Co.,
St. Louis, MO, USA) vapor while under vacuum for 3 h. Anandamide
and WIN55212-2 were obtained from RBI (Batick, MA, USA). HU-
210 was obtained from Tocris (Ballwin, MO, USA). [3H]WIN55212-2
and [125I]cAMP were purchased from New England Nuclear (Boston,
MA, USA).
2.2. Amino acid numbering system
The amino acid numbering system suggested by Ballesteros and
Weinstein [23] was used. Each amino acid identi¢er starts with the
transmembrane helix number, followed by the amino acid position
relative to a reference amino acid in that helix. This reference amino
acid is the most highly conserved residue across G protein-coupled
receptors in that helix and is assigned a locant value of 0.50. This
numbering system for the cannabinoid receptor has been previously
described [24].
2.3. Mutagenesis
A 1.8 kb full-length human CB2 cDNA was subcloned into pRC/
CMV (Invitrogen, San Diego, CA, USA) to construct the expression
plasmid pHCB2-RC/CMV [25]. The GeneEditor in vitro site-directed
mutagenesis system (Promega, Madison, WI, USA) was used to mu-
tate the CB2 receptor. For CB2L5.50P, the mutagenic oligonucleotide
5P-TCGCCTTCCCCTTTTCCGG-3P was used. For CB2Y5.58A, the
mutagenic oligonucleotide 5P-ATCATCTACACCGCTGGGCATGT-
TCTC-3P was used. The presence of the mutation and the accuracy of
the DNA sequences were con¢rmed by dideoxy sequencing.
2.4. Cell transfection and culture
Expression plasmids containing wild-type and mutant cannabinoid
receptors transfected into human embryonic kidney 293 cells. Trans-
fected cells were selected in culture medium containing 500 Wg/ml
geneticin, and cell lines stably expressing wild-type and mutant can-
nabinoid receptors were established according to a previously estab-
lished method [26]. Cells were grown as monolayers in Dulbecco’s
modi¢ed Eagle’s medium, containing 10% fetal bovine serum, gluta-
mine (2 mM), penicillin (100 U/ml), and streptomycin (100 Wg/ml) in a
humidi¢ed atmosphere consisting of 5% CO2 and 95% air, at 37‡C.
2.5. Ligand binding
For binding assays, cannabinoid ligand dilutions were made in
binding bu¡er containing 25 mg/ml bovine serum albumin and then
added to assay tubes. [3H]WIN55212-2 (2 nM) was used as a labeled
ligand for competition binding assays. Non-speci¢c binding was de-
termined in the presence of 1 WM unlabeled WIN55212-2. Binding
assays were performed in 0.5 ml of binding bu¡er containing 5 mg/
ml bovine serum albumin for 60 min at 30‡C. Free and bound radio-
ligands were separated by rapid ¢ltration through polyethylenimine-
treated GF/B ¢lters (Whatman International, Maidstone, UK) that
had been soaked in cold wash bu¡er (50 mM Tris^HCl, pH 7.4,
and 1 mg/ml of bovine serum albumin). The ¢lters were washed three
times with 3 ml cold wash bu¡er. The bound [3H]WIN55212-2 was
determined by liquid scintillation counting after overnight equilibra-
tion of the ¢lter in 5 ml of scintillation cocktail (Hydro£uor, National
Diagnostics, Manville, NJ, USA).
2.6. cAMP accumulation
To prevent the hydrolysis of cAMP, cells were incubated with 0.2
mM of Ro 20-1724, a phosphodiesterase inhibitor. Aliquot of cells
(200 Wl) were added to tubes containing forskolin and S cannabinoids
in a total volume of 250 Wl and incubated for 10 min at 37‡C. The
reaction was terminated by the addition of 250 Wl of 0.1 N HCl. 50 Wl
of the reaction solution was assayed for cAMP. Measurement of
cAMP was performed by radioimmunoassay using [125I]cAMP (Du-
Pont-NEN, Wilmington, DE, USA). The results are expressed as per-
cent inhibition of forskolin-stimulated cAMP accumulation.
2.7. Data analysis
Data from ligand binding and cAMP accumulation assays were
analyzed, and curves were generated with use of the Prism program
(GraphPad Software, San Diego, CA, USA). IC50 and EC50 values
were determined through non-linear regression analysis performed
with the Prism program. Kd and Bmax values were estimated from
competition binding experiments with the following equations:
Kd = IC503L and Bmax = (B0IC50)/L, where L is the concentration of
free radioligand, and B0 is speci¢cally bound radioligand [27]. The Ki
values were calculated based on the Cheng-Pruso¡ equation:
Ki = IC50/(1+L/Kd) [28].
3. Results
3.1. Comparison between wild-type and mutant CB2 receptors
for ligand binding
Radioligand binding assays were performed to compare
wild-type and mutant CB2 receptors. Speci¢c high-a⁄nity
binding of cannabinoid ligand [3H]WIN55212-2 was observed
with membranes prepared from 293 cells stably expressing wild-
type CB2 receptor (Fig. 2). The Kd and Bmax were determined
to be 4.8S 0.4 nM and 2210.0S 373.5 fmol/mg protein, respec-
Fig. 1. Schematic view of the putative ¢fth transmembrane domain
of the human CB2 cannabinoid receptor showing the amino acid se-
quence and positions of L5.50 and Y5.58. Letters in circles indicate
the amino acid types. Two black circles indicate the positions where
the mutations were made in this study.
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tively. The CB2L5.50P mutation completely abolished ligand
binding (data not shown). In contrast, speci¢c high-a⁄nity
binding of [3H]WIN55212-2 was observed with CB2Y5.58A
mutant receptor (Fig. 2). The Kd and Bmax values were deter-
mined to be 37.2S 7.9 nM and 2256.0S 505.7 fmol/mg protein,
respectively. HU-210 and anandamide, two cannabinoid li-
gands with distinct chemical structures, were tested for their
ability to compete for speci¢c [3H]WIN55212-2 binding (Fig.
2). The CB2Y5.58A mutation resulted in a rightward shift of
the competition curves, as compared with the wild-type CB2.
For HU-210, the Ki values for wild-type CB2 and CB2Y5.58A
were 0.62S 0.14 and 3.0S 1.1 nM, respectively. For anandam-
ide, the Ki values for wild-type CB2 and CB2Y5.58A were
687.5S 176.3 and 2936.0S 137.5 nM, respectively.
3.2. Comparison between wild-type and mutant CB2 receptors
for inhibition of forskolin-stimulated cAMP accumulation
cAMP accumulation assays were conducted to compare
wild-type and mutant CB2 receptors (Figs. 3 and 4). In 293
cells stably expressing wild-type CB2, three cannabinoid li-
gands inhibited forskolin-stimulated cAMP accumulation in
a concentration-dependent manner. The EC50 values for
WIN55212-2, HU-210, and anandamide were 0.71 S 0.14,
0.28S 0.07, and 93.3 S 25.8 nM, respectively. In contrast, in
293 cells stably transfected with CB2L.50P and CB2Y5.58A
receptors, these three cannabinoid agonists completely lost
their ability to inhibit forskolin-stimulated cAMP accumula-
tion.
4. Discussion
About 84% of G protein-coupled receptors have a con-
served proline (P5.50) at the ¢fth transmembrane domain
[17]. However, in cannabinoid receptors this conserved proline
is missing, instead, a leucine is located at the corresponding
position [24]. In this study, the CB2L5.50P mutation com-
pletely eliminated ligand binding and agonist-induced inhibi-
tion of cAMP accumulation, indicating that the replacement
of conserved proline by leucine at position 5.50 of CB2 is
critical for the functions of this receptor.
Presently, it is unknown why the CB2L5.50P mutation
caused a complete loss of function of the CB2 receptor. Pro-
line is considered the classical helix-breaker [18^20], thus the
introduction of CB2L5.50P mutation into the ¢fth trans-
membrane domain of CB2 would create a kink in the helical
backbone. Most G protein-coupled receptors have a highly
conserved proline at the fourth, ¢fth, sixth, and seventh trans-
membrane domains. On the other hand, there is no conserved
proline in the ¢rst, second, and third transmembrane do-
mains. It is likely that the presence of both ‘angled’, pro-
line-containing, and ‘straight’, proline-lacking helices is im-
portant for the relative movements of helical bundles that
are necessary for receptor activation. Cannabinoid receptors
have the conserved proline at the fourth, sixth, and seventh
transmembrane domains, but the conserved proline at the ¢fth
transmembrane domain is missing. The current study on CB2
indicates that the ‘straight’, proline-lacking ¢fth transmem-
brane domain is crucial for the function of this receptor.
In the current study, Y5.58 was selected for mutational
analysis because it is highly conserved in most G protein-
coupled receptors, it is very close to the third intracellular
loop, and it has been shown to be a critical amino acid for
receptor activation in other G protein-coupled receptors. We
wanted to test whether in the absence of P5.50, this tyrosine
Fig. 2. Comparison between wild-type CB2 and CB2Y5.58A receptors for ligand binding. Competition binding assays were performed on mem-
branes prepared from 293 cells stably expressing wild-type CB2 or CB2Y5.58A mutant receptor. [3H]WIN55212-2 was used as a labeled ligand
for competition binding assays. Membranes containing wild-type CB2 and CB2Y5.58A mutant receptors were incubated with various concen-
trations of ligands for 60 min at 30‡C. Points, meanSS.E.M. of three independent experiments performed in duplicate. Curves were generated
with use of the Prism program. Squares represent wild-type CB2 and triangles represent CB2Y5.58A receptors.
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Fig. 3. Comparison between wild-type CB2 and CB2L5.50P receptors for agonist-induced inhibition of cAMP accumulation. cAMP accumula-
tion assays were performed on 293 cells stably expressing wild-type CB2 or CB2L5.50P mutant receptor. Measurement of cAMP was carried
out by radioimmunoassay using [125I]cAMP. Cells expressing wild-type CB2 and CB2L5.50P mutant receptors were incubated with various con-
centrations of ligands for 10 min at 37‡C. The results are expressed as percent forskolin-stimulated cAMP accumulation. Points, meanSS.E.M.
of three independent experiments performed in triplicate. Curves were generated with use of the Prism program. Squares represent wild-type
CB2 and circles represent CB2L5.50P receptors.
Fig. 4. Comparison between wild-type CB2 and the CB2Y5.58A receptors for agonist-induced inhibition of cAMP accumulation. cAMP accu-
mulation assays were performed on 293 cells stably expressing wild-type CB2 or CB2Y5.58A mutant receptor. Measurement of cAMP was car-
ried out by radioimmunoassay using [125I]cAMP. Cells expressing wild-type CB2 and CB2Y5.58A mutant receptors were incubated with various
concentrations of ligands for 10 min at 37‡C. The results are expressed as percent forskolin-stimulated cAMP accumulation. Points, meanS
S.E.M. of three independent experiments performed in triplicate. Curves were generated with use of the Prism program. Squares represent wild-
type CB2 and triangles represent CB2Y5.58A receptors.
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was still crucial for the activation of CB2. The CB2Y5.58A
mutation caused a reduction in agonist binding a⁄nities in the
current study. Since Y5.58 is located at the bottom of the ¢fth
transmembrane domain, the decrease in agonist binding a⁄n-
ities in the CB2Y5.58A mutant receptor is most likely due to
indirect, conformational changes on the ligand-binding pock-
et, rather than direct e¡ects on the ligand binding sites.
CB2Y5.58A mutation completely abolished cannabinoid-in-
duced inhibition of cAMP accumulation in cells stably ex-
pressing CB2. These data are consistent with previous reports
on the critical roles of this tyrosine in the activation of angio-
tensin II and neurokinin-1 receptors [21,22]. Currently, the
exact roles for this highly conserved tyrosine in the activation
of G protein-coupled receptors are not clear. A recent study
by Howlett et al. [29] suggested that N-terminal portion of the
third cytoplasmic loop of CB1 are very important for inter-
acting with G proteins. Y5.58 is located at the bottom of the
¢fth transmembrane domain, a position adjacent to the N-
terminal of the third cytoplasmic loop. Modeling studies
have suggested that this amino acid is in molecular proximity
to regions that are important in receptor activation, including
the DRY motif located at the end of the third transmembrane
helix [22]. Therefore, this conserved tyrosine may play an
important role in propagation of the signal from the ligand
binding domain to the third cytoplasmic loop of these recep-
tors. Replacement of the tyrosine with an alanine may impair
the proper propagation of the agonist-induced conformational
changes of the receptor.
In summary, the present study provides experimental evi-
dences to support the conclusion that a ‘straight’, proline-
lacking ¢fth transmembrane, and a highly conserved tyrosine
residue located at the bottom of the ¢fth transmembrane do-
main, play critical roles in the functions of CB2.
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